MX2023014092A - Acido nucleico antisentido. - Google Patents
Acido nucleico antisentido.Info
- Publication number
- MX2023014092A MX2023014092A MX2023014092A MX2023014092A MX2023014092A MX 2023014092 A MX2023014092 A MX 2023014092A MX 2023014092 A MX2023014092 A MX 2023014092A MX 2023014092 A MX2023014092 A MX 2023014092A MX 2023014092 A MX2023014092 A MX 2023014092A
- Authority
- MX
- Mexico
- Prior art keywords
- oligonucleotide
- nucleotide sequence
- seq
- target region
- nucleotide
- Prior art date
Links
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 230000000692 anti-sense effect Effects 0.000 title 1
- 239000002773 nucleotide Substances 0.000 abstract 10
- 125000003729 nucleotide group Chemical group 0.000 abstract 10
- 108091034117 Oligonucleotide Proteins 0.000 abstract 8
- 101000804798 Homo sapiens Werner syndrome ATP-dependent helicase Proteins 0.000 abstract 2
- 230000000295 complement effect Effects 0.000 abstract 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 102000044881 human WRN Human genes 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/04—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; involved in cellular and subcellular movement (3.6.4)
- C12Y306/04012—DNA helicase (3.6.4.12)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021090359 | 2021-05-28 | ||
| PCT/JP2022/021818 WO2022250155A1 (ja) | 2021-05-28 | 2022-05-27 | アンチセンス核酸 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014092A true MX2023014092A (es) | 2023-12-11 |
Family
ID=84228935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014092A MX2023014092A (es) | 2021-05-28 | 2022-05-27 | Acido nucleico antisentido. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250084411A1 (https=) |
| EP (1) | EP4349987A1 (https=) |
| JP (1) | JPWO2022250155A1 (https=) |
| KR (1) | KR20240013202A (https=) |
| CN (1) | CN117500925A (https=) |
| AU (1) | AU2022279820A1 (https=) |
| CA (1) | CA3221758A1 (https=) |
| MX (1) | MX2023014092A (https=) |
| TW (1) | TW202313975A (https=) |
| WO (1) | WO2022250155A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4342498A4 (en) * | 2021-05-13 | 2025-01-08 | National University Corporation Chiba University | ANTISENSE OLIGOMER |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3398378B2 (ja) | 1989-12-20 | 2003-04-21 | アンチビラルス・インコーポレイテツド | リン含有キラルインターサブユニットリンケージを有する非電荷モルホリノ―基体ポリマー |
| MX2010004955A (es) | 2007-11-15 | 2010-06-30 | Avi Biopharma Inc | Metodo de sintesis de oligomeros de morfolina. |
| CN112574988A (zh) * | 2008-10-24 | 2021-03-30 | 萨雷普塔治疗公司 | 用于dmd的多外显子跳跃组合物 |
| AU2010312751B2 (en) | 2009-10-29 | 2014-07-24 | Osaka University | Bridged artificial nucleoside and nucleotide |
| US10377789B2 (en) | 2012-09-21 | 2019-08-13 | Osaka University | Oligonucleotide and artificial nucleoside having guanidine bridge |
| WO2015125783A1 (ja) | 2014-02-18 | 2015-08-27 | 国立大学法人大阪大学 | 架橋型ヌクレオシドおよびヌクレオチド |
-
2022
- 2022-05-27 TW TW111119953A patent/TW202313975A/zh unknown
- 2022-05-27 CN CN202280038163.1A patent/CN117500925A/zh active Pending
- 2022-05-27 KR KR1020237044656A patent/KR20240013202A/ko active Pending
- 2022-05-27 MX MX2023014092A patent/MX2023014092A/es unknown
- 2022-05-27 US US18/564,976 patent/US20250084411A1/en active Pending
- 2022-05-27 JP JP2023524257A patent/JPWO2022250155A1/ja active Pending
- 2022-05-27 CA CA3221758A patent/CA3221758A1/en active Pending
- 2022-05-27 AU AU2022279820A patent/AU2022279820A1/en active Pending
- 2022-05-27 WO PCT/JP2022/021818 patent/WO2022250155A1/ja not_active Ceased
- 2022-05-27 EP EP22811423.7A patent/EP4349987A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2022250155A1 (https=) | 2022-12-01 |
| AU2022279820A1 (en) | 2023-12-14 |
| EP4349987A1 (en) | 2024-04-10 |
| CN117500925A (zh) | 2024-02-02 |
| KR20240013202A (ko) | 2024-01-30 |
| CA3221758A1 (en) | 2022-12-01 |
| WO2022250155A1 (ja) | 2022-12-01 |
| AU2022279820A9 (en) | 2024-01-04 |
| TW202313975A (zh) | 2023-04-01 |
| US20250084411A1 (en) | 2025-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rusecka et al. | Nuclear genes involved in mitochondrial diseases caused by instability of mitochondrial DNA | |
| Topper et al. | Characterization of human MRP/Th RNA and its nuclear gene: full length MRP/Th RNA is an active endoribonuclease when assembled as an RNP | |
| Pays et al. | Trypanosoma brucei: constitutive activity of the VSG and procyclin gene promoters. | |
| Hixson et al. | Both the conserved stem-loop and divergent 5'-flanking sequences are required for initiation at the human mitochondrial origin of light-strand DNA replication. | |
| CN114174510A (zh) | 添加了功能性碱基序列的靶标编辑指导rna | |
| JP2024050747A5 (https=) | ||
| Willers et al. | miR-127-5p targets the 3′ UTR of human β-F1-ATPase mRNA and inhibits its translation | |
| FI4025691T3 (fi) | Uusia, luonnossa esiintymättömiä CRISPR-CAS-nukleaaseja genomin muokkausta varten | |
| Asagoshi et al. | DNA polymerase β-dependent long patch base excision repair in living cells | |
| Lonergan et al. | The ribosomal RNA gene region in Acanthamoeba castellanii mitochondrial DNA: a case of evolutionary transfer of introns between mitochondria and plastids? | |
| MX2023014092A (es) | Acido nucleico antisentido. | |
| JP2014100144A (ja) | ポリヌクレオチド及びその用途 | |
| CL2022001482A1 (es) | Gen cca para la resistencia a los virus | |
| MX2021005507A (es) | Oligonucleotidos de angptl4 que influyen en la regulacion del metabolismo de los acidos grasos. | |
| PE20001023A1 (es) | Deshidrogenasa de xilitol de bacterias de acido acetico y su gen | |
| BR112023027398A2 (pt) | Produtos e composições | |
| AR107578A1 (es) | Plantas tolerantes a las bajas temperaturas | |
| WO2019063792A3 (en) | OLIGONUCLEOTIDE INHIBITING CHOP EXPRESSION | |
| MX2024012034A (es) | Ácidos nucleicos antisentido para usarse en el tratamiento de portadores de mutaciones lmna | |
| WO2022266486A3 (en) | Products and compositions | |
| CN114008063A (zh) | 用于dna和rna聚合和测序的修饰的核苷酸和方法 | |
| Hajduk et al. | Mitochondrial mRNA editing in kinetoplastid protozoa | |
| Galligan et al. | Retroplasmids: linear and circular plasmids that replicate via reverse transcription | |
| AR094337A1 (es) | Método y composiciones para el control genético de insectos plaga en plantas de algodón a través del silenciamiento de genes de quitina sintasas | |
| Tchurikov et al. | Suffix-specific RNAi leads to silencing of F element in Drosophila melanogaster |